The presence of comorbidity in tourette syndrome increases the need for pharmacological treatment

Journal of Child Neurology

Volumn 24, Issue 12, 2009, Pages 1504-1512

  Debes, Nanette M M M ^a   Hjalgrim, Helle ^a   Skov, Liselotte ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Comorbidity; Pharmacology; Tourette syndrome

Indexed keywords

CLONIDINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMORBIDITY; CONTROLLED STUDY; DENMARK; DIET SUPPLEMENTATION; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; TIC;

ADOLESCENT; ANTICONVULSANTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COGNITIVE THERAPY; COHORT STUDIES; COMORBIDITY; DENMARK; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; NEUROPHARMACOLOGY; OBSESSIVE-COMPULSIVE DISORDER; SCANDINAVIA; SEROTONIN UPTAKE INHIBITORS; TOURETTE SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70449955796     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073808331363     Document Type: Article

References (41)

1. Rampello L., Alvano A., Battaglia G., Bruno V., Raffaele R., Nicoletti F. Tic disorders: from pathophysiology to treatment. J Neurol. 2006 ; 253: 1-15.
2. Sandor P. Pharmacological management of tics in patients with TS. J Psychosom Res. 2003 ; 55: 41-48.
3. Gilbert DL, Lipps TD Tourettes syndrome. Curr Treat Options Neurol. 2005 ; 7: 211-219.
4. Singer HS Tourettes syndrome: from behaviour to biology. Lancet Neurol. 2005 ; 4: 149-159.
5. Kienast T., Heinz A. Dopamine and the diseased brain. CNS Neurol Disord Drug Targets. 2006 ; 5: 109-131.
6. Robertson MM Tourette syndrome, associated conditions and the complexities of treatment. Brain. 2000 ; 123: 425-462.
7. Scahill L., Erenberg G., Berlin CM Jr, et al. Tourette Syndrome Association Medical Advisory Board: Practice Committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRX. 2006 ; 3: 192-206.
8. Shavitt RG, Hounie AG, Rosario Campos MC, Miguel EC Tourettes syndrome. Psychiatr Clin North Am. 2006 ; 29: 471-486.
9. Olsen LL, Singer HS, Goodman WK, Maria BL Tourette syndrome: diagnosis, strategies, therapies, pathogenesis, and future research directions. J Child Neurol. 2006 ; 21: 630-641.
10. Russell VA, Sagvolden T., Johansen EB Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct. 2005 ; 1: 9.
11. Robertson MM, Eapen V. Pharmacologic controversy of CNS stimulants in Gilles de la Tourettes syndrome. Clin Neuropharmacol. 2005 ; 15: 408-425.
12. Robertson MM Attention deficit hyperactivity disorder, tics and Tourettes syndrome: the relationship and treatment implications. A commentary. Eur Child Adolesc Psychiatry. 2006 ; 15: 1-11.
13. Erenberg G. The relationship between tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol. 2005 ; 12: 217-221.
14. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005 ; 65: 1941-1949.
15. Hesse S., Muller U., Lincke T., et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 2005 ; 140: 63-72.
16. van der Wee NJ, Stevens H., Hardeman JA, et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry. 2004 ; 161: 2201-2206.
17. March JS, Franklin ME, Leonard H., et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2007 ; 61: 344-347.
18. Miguel EC, Shavitt RG, Ferrao YA, Brotto SA, Diniz JB How to treat OCD in patients with Tourette syndrome. J Psychosom Res. 2003 ; 55: 49-57.
19. Azrin NH, Nunn RG Habit-reversal: a method of eliminating nervous habits and tics. Behav Res Ther. 1973 ; 11: 619-628.
20. Deckersbach T., Rauch S., Buhlmann U., Wilhelm S. Habit reversal versus supportive psychotherapy in Tourettes disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther. 2006 ; 44: 1079-1090.
21. Peterson AL, Azrin NH An evaluation of behavioral treatments for Tourette syndrome. Behav Res Ther. 1992 ; 30: 167-174.
22. Verdellen CW, Keijsers GP, Cath DC, Hoogduin CA Exposure with response prevention versus habit reversal in Tourettess syndrome: a controlled study. Behav Res Ther. 2004 ; 42: 501-511.
23. Wilhelm S., Deckersbach T., Coffey BJ, Bohne A., Peterson AL, Baer L. Habit reversal versus supportive psychotherapy for Tourettes disorder: a randomized controlled trial. Am J Psychiatry. 2003 ; 160: 1175-1177.
24. Woods DW, Twohig MP, Flessner CA, Roloff TJ Treatment of vocal tics in children with Tourette syndrome: investigating the efficacy of habit reversal. J Appl Behav Anal. 2003 ; 36: 109-112.
25. Himle MB, Woods DW, Piacentini JC, Walkup JT Brief review of habit reversal training for Tourette syndrome. J Child Neurol. 2006 ; 21: 719-725.
26. Qasaymeh MM, Mink JW New treatments for tic disorders. Curr Treat Options Neurol. 2006 ; 8: 465-473.
27. Grimaldi BL The central role of magnesium deficiency in Tourettes syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourettes syndrome and several reported comorbid conditions. Med Hypotheses. 2002 ; 58: 47-60.
28. Richardson AJ Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry. 2006 ; 18: 155-172.
29. Johnson M., Ostlund S., Franssen G., et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Attend Disord. IN PRESS
30. Mantel BJ, Meyers A., Tran QY, Rogers S., Jacobson JS Nutritional supplements and complementary/alternative medicine in Tourette syndrome. J Child Adolesc Psychopharmacol. 2004 ; 14: 582-589.
31. Bergin A., Waranch HR, Brown J., Carson K., Singer HS Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol. 1998 ; 18: 136-142.
32. Sandor P., Stephens RJ Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol. 2000 ; 20: 710-712.
33. Robertson MM, Stern JS Gilles de la Tourette syndrome: symptomatic treatment based on evidence. Eur Child Adolesc Psychiatry. 2000 ; 9: 160-175.
34. Rasmussen NH Diagnosis of ADHD, hyperkinetic disturbance, and DAMP in children. A review. Ugeskr L■ger. 2002 ; 164: 4631-4636.
35. Debes NM, Hjalgrim H., Skov L. Validation of the presence of co-morbidities in a Danish clinical cohort of children with Tourette syndrome. J Child Neurol. 2008 ; 23: 1017-1027.
36. Eapen V., Fox-Hiley P., Banerjee S., Robertson M. Clinical features and associated psychopathology in a Tourette syndrome cohort. Acta Neurol Scand. 2004 ; 109: 255-260.
37. Freeman RD, Fast DK, Burd L., Kerbeshian J., Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol. 2000 ; 42: 436-447.
38. Kadesjo B., Gillberg C. Tourettes disorder: epidemiology and comorbidity in primary school children. J Am Acad Child Adolesc Psychiatry. 2000 ; 39: 548-555.
39. Khalifa N., von Knorring AL Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. Acta Paediatr. 2005 ; 94: 1608-1614.
40. Ohta M., Kano Y. Clinical characteristics of adult patients with tics and/or Tourettes syndrome. Brain Dev. 2003 ; 25: S32 - S36.
41. Debes NM, Hjalgrim H., Skov L. Limited knowledge of Tourette syndrome causes delay in diagnosis. Neuropediatrics. 2008 ; 39: 101-105.